SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Von Muhlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995; 24: 32358.
  • 2
    Pisetsky DS. Anti-DNA and autoantibodies. Curr Opin Rheumatol 2000; 12: 3648.
  • 3
    Hahn BH. Antibodies to DNA. N Engl J Med 1998; 338: 135968.
  • 4
    Schett G, Steiner G, Smolen JS. Nuclear antigen histone H1 is primarily involved in lupus erythematosus cell formation. Arthritis Rheum 1998; 41: 144655.
  • 5
    Vianna JL, Haga HJ, Tripathi P, Cervera R, Khamashta MA, Hughes GR. Reassessing the status of antiphospholipid syndrome in systemic lupus erythematosus. Ann Rheum Dis 1992; 51: 1601.
  • 6
    Karpouzas GA, Hahn BH. Systemic lupus erythematosus. In: SmolenJS, LipskyPE, editors. Targeted therapies in rheumatology. London: Martin Dunitz; 2003. p. 56381.
  • 7
    Morris RJ, Guggenheim SJ, McIntosh RM, Rubin RL, Kohler PF. Simultaneous immunologic studies of skin and kidney in systemic lupus erythematosus: clinicopathologic correlations. Arthritis Rheum 1979; 22: 86470.
  • 8
    Van Bruggen MC, Kramers C, Walgreen B, Elema JD, Kallenberg CG, van den Borg J, et al. Nucleosomes and histones are present in glomerular deposits in human lupus nephritis. Nephrol Dial Transplant 1997; 12: 5766.
  • 9
    Madaio MP. The role of autoantibodies in the pathogenesis of lupus nephritis. Semin Nephrol 1999; 19: 4856.
  • 10
    Salmon JE, Kimberly RP, D'Agati V. Immunopathology. In: HochbergM, SilmanAS, SmolenJS, WeinblattMW, WeismannME, editors. Rheumatology. 3rd ed. London: Mosby; 2003. p. 1297315.
  • 11
    Hopkinson ND, Jenkinson C, Muir KR, Doherty M, Powell RJ. Racial group, socioeconomic status, and the development of persistent proteinuria in systemic lupus erythematosus. Ann Rheum Dis 2000; 59: 1169.
  • 12
    Balow JE, Boumpas DT, Austin HA III. New prospects for treatment of lupus nephritis. Semin Nephrol 2000; 20: 329.
  • 13
    Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001; 59: 215663.
  • 14
    Bao L, Haas M, Boackle SA, Kraus DM, Cunningham PN, Park P, et al. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol 2002; 168: 36017.
  • 15
    Watanabe H, Garnier G, Circolo A, Wetsel RA, Ruiz P, Holers VM, et al. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol 2000; 164: 78694.
  • 16
    Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998; 279: 10524.
  • 17
    O'Shea JJ, Ma A, Lipsky P. Cytokines and autoimmunity. Nat Rev Immunol 2002; 2: 3745.
  • 18
    Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001; 11: 3727.
  • 19
    Chan FK, Siegel RM, Lenardo MJ. Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity 2000; 13: 41922.
  • 20
    Feldmann M, Maini RN. Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Ann Rev Immunol 2001; 19: 16396.
  • 21
    Kollias G, Douni E, Kassiotis G, Kontoyiannis D. The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis 1999; 58: 1329.
  • 22
    Dinarello CA. Proinflammatory cytokines. Chest 2000; 118: 5038.
  • 23
    Aringer M, Stummvoll GH, Steiner G, Koller M, Steiner CW, Hofler E, et al. Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology (Oxford) 2001; 40: 87681.
  • 24
    Aringer M, Feierl E, Steiner G, Stummvoll GH, Hofler E, Steiner CW, et al. Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus 2002; 11: 1028.
  • 25
    Gabay C, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer JM, et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997; 24: 3038.
  • 26
    Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor α and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996; 35: 106774.
  • 27
    Meijer C, Huysen V, Smeenk RT, Swaak AJ. Profiles of cytokines (TNFα and IL-6) and acute phase proteins (CRP and α1AG) related to the disease course in patients with systemic lupus erythematosus. Lupus 1993; 2: 35965.
  • 28
    Aderka D, Wysenbeek A, Engelmann H, Cope AP, Brennan F, Molad Y, et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993; 36: 111120.
  • 29
    Maury CP, Teppo AM. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum 1989; 32: 14650.
  • 30
    Malide D, Russo P, Bendayan M. Presence of tumor necrosis factor α and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol 1995; 26: 55864.
  • 31
    Aringer M, Zimmermann C, Graninger WB, Petera P, Stockl S, Steiner G, et al. TNFα is an essential mediator in lupus nephritis. [abstract] Arthritis Rheum 2002; 46: 34189.
  • 32
    Takemura T, Yoshioka K, Murakami K, Akano N, Okada M, Aya N, et al. Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Arch 1994; 424: 45964.
  • 33
    Herrera-Esparza R, Barbosa-Cisneros O, Villalobos-Hurtado R, Avalos-Diaz E. Renal expression of IL-6 and TNFα genes in lupus nephritis. Lupus 1998; 7: 1548.
  • 34
    Debets JM, Van der Linden CJ, Dieteren IE, Leeuwenberg JF, Buurman WA. Fc-receptor cross-linking induces rapid secretion of tumor necrosis factor (cachectin) by human peripheral blood monocytes. J Immunol 1988; 141: 1197201.
  • 35
    Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. [letter] Lancet 2002; 359: 57980.
  • 36
    Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 238390.
  • 37
    Smolen J, Steiner G, Breedveld FC, Kalden JR, Lipsky PE, Maini RN, et al. Anti-TNF therapy and drug induced lupus-like syndome. [abstract] Ann Rheum Dis 1999; 58 Suppl 1: 217.
  • 38
    Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001; 345: 34050.
  • 39
    Ferraccioli GF, Assaloni R, Di Poi E, Gremese E, De Marchi G, Fabris M. Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial. Rheumatology (Oxford) 2002; 41: 110912.
  • 40
    Jacob CO, McDevitt HO. Tumour necrosis factor-α in murine autoimmune ‘lupus’ nephritis. Nature 1988; 331: 3568.
  • 41
    Kontoyiannis D, Pasparakis M, Kollias G. Defective TNF/TNFR functioning supports the development of systemic autoimmunity. [abstract] Clin Exp Rheumatol 2002; 20: 262.
  • 42
    Gordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol 1989; 52: 42134.
  • 43
    Moore KJ, Yeh K, Naito T, Kelley VR. TNF-α enhances colony-stimulating factor-1-induced macrophage accumulation in autoimmune renal disease. J Immunol 1996; 157: 42732.
  • 44
    Brennan DC, Yui MA, Wuthrich RP, Kelley VE. Tumor necrosis factor and IL-1 in New Zealand black/white mice: enhanced gene expression and acceleration of renal injury. J Immunol 1989; 143: 34705.
  • 45
    Boswell JM, Yui MA, Burt DW, Kelley VE. Increased tumor necrosis factor and IL-1β gene expression in the kidneys of mice with lupus nephritis. J Immunol 1988; 141: 30504.
  • 46
    Yokoyama H, Kreft B, Kelley VR. Biphasic increase in circulating and renal TNF-α in MRL-lpr mice with differing regulatory mechanisms. Kidney Int 1995; 47: 12230.
  • 47
    Tsai CY, Wu TH, Huang SF, Sun KH, Hsieh SC, Han SH, et al. Abnormal splenic and thymic IL-4 and TNF-α expression in MRL-lpr/lpr mice. Scand J Immunol 1995; 41: 15763.
  • 48
    Bencivelli W, Vitali C, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. Clin Exp Rheumatol 1992; 10: 549-54.
  • 49
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 50
    Schmaldienst S, Mullner M, Goldammer A, Spitzauer S, Banyai S, Horl WH, et al. Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases? Rheumatology (Oxford) 2001; 40: 51321.
  • 51
    Schett G, Rubin RL, Steiner G, Hiesberger H, Muller S, Smolen J. The lupus erythematosus cell phenomenon: comparative analysis of antichromatin antibody specificity in lupus erythematosus cell–positive and –negative sera. Arthritis Rheum 2000; 43: 4208.
  • 52
    Smolen JS, Butcher B, Fritzler MJ, Gordon T, Hardin J, Kalden JR, et al. Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and Western blotting. Arthritis Rheum 1997; 40: 4138.
  • 53
    Aringer M, Smolen JS. Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Res Ther 2003; 5: 1727.
  • 54
    Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 11257.
  • 55
    Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 134652.
  • 56
    Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002; 47: 50612.
  • 57
    Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 26737.
  • 58
    Pisetsky DS. Tumor necrosis factor α blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum 2000; 43: 23812.